SCHEMBL4008992

SCHEMBL4008992

COc1ccc(S(=O)(=O)NCC2CCC(CNC(=O)NCc3ccccc3Cl)CC2)cc1OC

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.64
THRB P10828 1/20 0.59
KMT2A Q03164 3/20 0.57
MEN1 O00255 2/20 0.57
ATM Q13315 1/20 0.57
MAPT P10636 2/20 0.56
LMNA P02545 1/20 0.53
ALDH1A1 P00352 2/20 0.53
POLB P06746 2/20 0.53
ADRA1A P35348 2/20 0.52
ADRA1B P35368 2/20 0.52
TP53 P04637 2/20 0.50
ALPL P05186 1/20 0.49
ALPI P09923 1/20 0.49
ALPG P10696 1/20 0.49
HTT P42858 1/20 0.48
ACACB O00763 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4009437 0.84 THRB (0.68) MAPK1THRBKMT2AMEN1ATM
SCHEMBL4003492 0.84 THRB (0.64) THRBKMT2AMEN1ATMMAPT
SCHEMBL4004972 0.82 MEN1 (0.61) KMT2AMEN1ATMMAPTLMNA
SCHEMBL4008982 0.81 ALDH1A1 (0.67) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL4389873 0.75 TP53 (0.49) THRBKMT2AMEN1ATMMAPT
SCHEMBL13850376 0.71 MAPK1 (0.62) MAPK1KMT2AMEN1ATMALDH1A1
SCHEMBL7420169 0.70 MAPK1 (0.76) MAPK1KMT2AMAPTLMNAALDH1A1
SCHEMBL4005992 0.70 KMT2A (0.53) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL4008674 0.70 MAPT (0.66) MAPK1KMT2AMEN1ATMMAPT
SCHEMBL4008429 0.69 LMNA (0.52) KMT2AMEN1MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306133-A1 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 ASTRAZENECA AB (SE) 2009-12-10 US claimed
WO-2009082346-A1 NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 ASTRAZENECA AB (SE) 2009-07-02 WO claimed
US-20090306133-A1 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 ASTRAZENECA AB (SE) 2009-12-10 US disclosed
WO-2009082346-A1 NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087 ASTRAZENECA AB (SE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306133-A1 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087 ACACA, ACACB, ACAT1 MAPK1 2528/4885THRB 1586/4885KMT2A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.